RT Journal Article
SR Electronic
T1 Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study
JF ERJ Open Research
JO erjor
FD European Respiratory Society
SP 00443-2021
DO 10.1183/23120541.00443-2021
A1 Paola Faverio
A1 Alessia Fumagalli
A1 Sara Conti
A1 Fabiana Madotto
A1 Francesco Bini
A1 Sergio Harari
A1 Michele Mondoni
A1 Tiberio Oggionni
A1 Emanuela Barisione
A1 Paolo Ceruti
A1 Maria Chiara Papetti
A1 Bruno Dino Bodini
A1 Antonella Caminati
A1 Angela Valentino
A1 Stefano Centanni
A1 Donatella Noè
A1 Matteo Della Zoppa
A1 Silvia Crotti
A1 Marco Grosso
A1 Samir Giuseppe Sukkar
A1 Denise Modina
A1 Marco Andreoli
A1 Roberta Nicali
A1 Giulia Suigo
A1 Federica De Giacomi
A1 Sara Busnelli
A1 Elena Cattaneo
A1 Lorenzo Giovanni Mantovani
A1 Giancarlo Cesana
A1 Alberto Pesci
A1 Fabrizio Luppi
YR 2021
UL http://openres.ersjournals.com/content/early/2021/09/29/23120541.00443-2021.abstract
AB Background Nutritional status (NS) impacts on quality of life and prognosis of patients with respiratory diseases including idiopathic pulmonary fibrosis (IPF). However, there is a lack of studies performing an extensive nutritional assessment of IPF patients. This study aims to investigate the NS and to identify nutritional phenotypes in a cohort of IPF patients at diagnosis.Methods Patients underwent a thorough pulmonary and nutritional evaluation including questionnaires on NS and physical activity, anthropometry, body impedence, dynamometry, 4-meter gait speed and blood tests.Results 90 IPF patients (78.9% males, mean age 72.7 years) were enrolled. The majority of patients were classified as Gender-Age-Physiology Index stage 2 (47, 52.2%) with an inactive lifestyle according to International Physical Activity Questionnaire score (39, 43.3%) and had mean forced vital capacity and diffusing capacity for carbon monoxide 86.5% and 54.2%, respectively. In regards to nutritional phenotypes, the majority of patients were normally nourished (67.8%, 95% Confidence Interval (CI):58.6–77.7), followed by non-sarcopenic obese (25.3%, 95%CI:16.1–35.2), sarcopenic (4.6%, 95%CI:0.0–14.5) and sarcopenic obese (2.3%, 95%CI:0.0–12.2). Among normally nourished, 49.2% showed early signs of nutritional and physical performance alterations, including body mass index≥ 30 in 4.3%, history of weight loss≥ 5% in 11.9%, reduction of gait speed and hand grip strength in 11.9% and 35.6%, respectively. Low vitamin D values were observed in 56.3% of cases.Conclusions IPF patients at diagnosis are mainly normally nourished and obese, but early signs of nutritional and physical performance impairment can already be identified at this stage.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Dr. Faverio reports personal fees from Boeringher ingelheim, grants from Roche, outside the submitted work; .Conflict of interest: Dr. Fumagalli has nothing to disclose.Conflict of interest: Dr. Conti has nothing to disclose.Conflict of interest: Dr. Madotto has nothing to disclose.Conflict of interest: Dr. Bini has nothing to disclose.Conflict of interest: Dr. Harari reports personal fees from Actelion, personal fees from Roche, personal fees from Boehringer Ingelheim, outside the submitted work; .Conflict of interest: Dr. Mondoni has nothing to disclose.Conflict of interest: Dr. Oggionni has nothing to disclose.Conflict of interest: Dr. Barisione reports personal fees from Chiesi farmaceutici, personal fees from Boeringher ingelheim, personal fees from Glasxosmithkline, outside the submitted work; .Conflict of interest: Dr. Ceruti has nothing to disclose.Conflict of interest: Dr. Papetti has nothing to disclose.Conflict of interest: Dr. Bodini has nothing to disclose.Conflict of interest: Dr. Caminati reports personal fees from Roche, personal fees from Boehringer Ingelheim, outside the submitted work; .Conflict of interest: Dr. Valentino has nothing to disclose.Conflict of interest: Prof. Centanni has nothing to disclose.Conflict of interest: Dr. Della Zoppa has nothing to disclose.Conflict of interest: Dr. Crotti has nothing to disclose.Conflict of interest: Dr. Grosso reports personal fees from Chiesi farmaceutici, personal fees from Johnson & Johnson, from null, outside the submitted work; .Conflict of interest: Dr. Sukkar has nothing to disclose.Conflict of interest: Dr. Modina has nothing to disclose.Conflict of interest: Dr. Andreoli has nothing to disclose.Conflict of interest: Dr. Nicali has nothing to disclose.Conflict of interest: Dr. Suigo has nothing to disclose.Conflict of interest: Dr. De Giacomi has nothing to disclose.Conflict of interest: Dr. Busnelli has nothing to disclose.Conflict of interest: Dr. Cattaneo has nothing to disclose.Conflict of interest: Dr. Mantovani has nothing to disclose.Conflict of interest: Dr. Cesana has nothing to disclose.Conflict of interest: Dr. Pesci has nothing to disclose.Conflict of interest: Dr. Luppi reports Lectures fee from Roche and from Boehringer-Ingelheim.Dr. Luppi reports and Lectures fee from Roche and from Boehringer-Ingelheim.